Speaker: Jarushka Naidoo

0:01:56

Dr. Jarushka Naidoo - Why did you choose to study lung cancer?

0:04:04

BTOG 2021 highlights: translational research in lung cancer

0:01:11

Unanswered questions regarding the use of IO in NSCLC

0:01:13

Exciting updates at the Gathering around Cancer meeting

0:00:48

Chemotherapy-free immunotherapy-based treatment approaches for NSCLC

0:00:55

Osimertinib for EGFR-mutant lung cancer

0:01:42

Management of Irish ALK+ NSCLC patients with brigatinib

0:03:58

Antibody drug conjugates in lung cancer

0:03:32

Multisystem immune-related AEs with immunotherapy in NSCLC

0:01:44

Post-hoc subgroup analysis from PACIFIC: durvalumab after CRT in unresectable stage III EGFRm NSCLC

1:55:34

Lung Cancer & Supportive Care: OncoAlert Colloquium Year in Review

0:01:28

Highlights in NSCLC from ASCO 2022

0:03:08

The management of oligometastatic and oligoremnant disease with local therapy

0:02:31

Differences in treating lung cancer with adjuvant and neoadjuvant immunotherapy

0:04:32

Key NSCLC updates

0:10:47

Lung Toxicities: Management of irAEs Guideline (Part 5)

0:01:45

The future of precision oncology in pancreatic cancer

0:02:21

Current treatment options for NSCLC without driver mutations

0:01:37

Treatment strategies for KRAS-mutant NSCLC with co-mutations

0:01:36

Is HER2-low a distinct subtype of breast cancer?

0:02:07

TWT-101: CFI-402411 alone or with pembrolizumab in patients with advanced tumors

0:01:13

Guiding NSCLC treatment with biomarkers

1:23:40

CTI/ISMO National Training Day – Session One: Integrating Trainees, RTs and Nurses into Research

0:01:48

Adjuvant and neoadjuvant chemo-IO for UK patients with NSCLC